Skip to content
montabiosciences.commontabiosciences.com
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact Us
MonTa Biosciences will be presenting very strong data on our immuno oncology technology at the annual meeting of AACR in Orlando
March 2, 2023

MonTa Biosciences will be presenting very strong data on our immuno oncology technology with our [...]

MonTa Biosciences open clinical sites in Madrid and Bruxelles
January 23, 2023

MonTa Bisciences have in January opened additionally 4 clinical sites in Madrid and Bruxelles. We [...]

MonTa Biosciences Announces Investment to Complete the Ongoing Phase I Monotherapy Trial on MBS8, and a Combination Phase IB/IIA Trial with MBS8 and a Currently Approved Oncology Drug.
October 19, 2022

COPENHAGEN, Denmark, October 20, 2022 — MonTa Biosciences, a clinical-stage biotechnology company focused on stimulating [...]

MonTa Biosciences featured in Nature pharmadealmakers magazine
March 28, 2022

MonTa Biosciences was featured as an upcoming biotech oncology company in Natures edition of pharmadealmakers. [...]

MonTa Biosciences successfully dose first patient in phase I clinical trial
April 23, 2021

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]

MonTa Biosciences awarded approval from regulatory agencies to start phase I study
January 18, 2021

MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]

MonTa Biosciences becomes a Clinical Stage Company
November 19, 2020

MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]

MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program
September 8, 2020

MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]

MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency
August 8, 2020

MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]

MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development
April 30, 2020

Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]

MonTa Biosciences close a Series A investment from existing investors to complete phase I in cancer patients
December 20, 2019

MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps [...]

Selected as an alumni case in the Nordic Mentoring Programme

MonTa Biosceinces was selected among successful biotech startups in the Nordic Mentoring Programme as an [...]

02
Dec
Attending the BioEurope conference in Hamburg
November 1, 2019

MonTa Biosciences is attending the BioEurope conference in Hamburg to meet with biotech and pharma companies [...]

Presenting data at the cancer immunotherapy SITC conference
October 30, 2019

MonTa Biosciences is attending the cancer immunotherapy SITC conference in Washington DC to present data on our [...]

Meeting with Key Opinion Leaders to plan phase I trial in patients
September 29, 2019

MonTa Biosciences attends the ESMO conference in Barcelona to meet with Key Opinion Leaders to [...]

Fireside interview at the IP-FAIR conference
May 2, 2019

MonTa Biosciences is invited to a fireside interview at the IP-FAIR conference in Copenhagen on May 8. [...]

Pharma business conference BioEurope in Vienna
March 20, 2019

MonTa Biosciences join the pharma business conference BioEurope in Vienna to meet with pharma and biotech [...]

Investment with Consolidated Holdings
January 30, 2019

MonTa Biosciences closes investment with Consolidated Holdings to secure future development towards clinical trials. Link [...]

Invitation to speak and join panel discussion at the NLSDays
July 5, 2018

MonTa Biosciences is invited to speak and join panel discussion with major Big Pharma companies Roche [...]

MonTa Biosciences attend Bio in Boston
May 30, 2018

MonTa Biosciences attend Bio in Boston from June 4-7th to meet and discuss partnership, collaborations and investment opportunities. Send [...]

  • 1
  • 2

MonTa Biosciences ApS

Diplomvej 381
2800 Kgs. Lyngby
Denmark

VAT nr. 36697016

    Privacy statement
    MonTa Biosciences - Cancer Therapeutics of Tomorrow
    • Home
    • About us
      • Company History
      • Management
      • Board of Directors
      • Founders
    • Technology
      • Todays Challenges
      • Cancer Treatment
      • Cancer Immunotherapy
      • Development
      • References
    • News
    • Contact Us